Reduction of hemorrhagic complications after non-focal renal biopsy with pre-procedure desmopressin administration
4 affiliations
- 1West Virginia School of Medicine, Charleston Division, West Virginia, United States of America
- 2Institute of Academic Medicine, Charleston Area Medical Center, West Virginia, United States of America
- 3Charleston Area Medical Center Nephrology, West Virginia, United States of America
- 4Charleston Area Medical Center, Interventional Radiology, Department of Surgery, West Virginia, United States of America
Abstract
PURPOSE: Ultrasound-guided non-focal renal biopsy (NFRB), which is performed to assess systemic renal processes, is associated with a 1.5%–14% bleeding risk. The goal of this study is to evaluate the safety and efficacy of 1-deamino-8-D-arginine vasopressin (DDAVP, or desmopressin) in mitigating bleeding risk when administered prior to NFRB.
METHODS: This retrospective observational study includes 158 patients who underwent NFRB between March 2022 and June 2025 at the study hospital before and after the implementation of a DDAVP administration protocol. Beginning in July 2023, every patient at the study site received intravenous DDAVP immediately before biopsy, regardless of renal function. Ultimately, 79 patients received DDAVP (the DDAVP group), and 79 did not receive the intervention (the non-DDAVP group). This study’s primary endpoint was clinically significant bleeding (resulting in unplanned admission; intervention for bleeding, such as angiography or surgery; and/or death) within 1 week of biopsy. Secondary endpoints were hyponatremia or a thromboembolic event within 1 week of biopsy. The data from patients in the two groups were compared using Mann–Whitney U tests for non-parametric data, Student’s t-tests for parametric data, and chi-squared tests for categorical data (with an alpha level of P < 0.05).
RESULTS: Six of the 79 patients (8%) in the non-DDAVP group experienced a clinically significant hemorrhage, compared with 0 in the DDAVP group (P = 0.03). Sodium levels were not significantly different between the two groups post-procedure (P = 0.43). There was no significant difference in the rate of thromboembolic events between the two groups [2/79 (2.5%) in the non-DDAVP group vs. 3/79 (3.8%) in the DDAVP group; P = 1.00]. The 5 patients (out of 158; 3.2%) who experienced a thromboembolic event within 1 week of NFRB had been on anticoagulants or antiplatelet agents that were held for biopsy.
CONCLUSION: DDAVP is associated with a reduction in unplanned hospitalizations and bleeding interventions (angiography and embolization) after NFRB, without an observed increase in thromboembolic events.
CLINICAL SIGNIFICANCE: Routine DDAVP administration before NRFB significantly reduces clinically significant bleeding, supporting its potential role as a simple prophylactic strategy.
Related
- Complications and management of thyroglossal duct cyst following Sistrunk procedure in children: a single-center retrospective study in Shanghai, China
- PO130 | HEMORRHAGIC AND THROMBOTIC COMPLICATIONS DURING DOACS TREATMENT: THE IMPORTANCE OF A REGULAR AND PROLONGED FOLLOW-UP
- PO022 | ARTIFICIAL INTELLIGENCE–ASSISTED PREDICTION OF THROMBOTIC AND HEMORRHAGIC COMPLICATIONS IN PATIENTS TREATED WITH VITAMIN K ANTAGONISTS: A RETROSPECTIVE EXPLORATORY STUDY
- Comparison of Open and Closed Reduction for Developmental Dysplasia of the Hip: A Retrospective Evaluation of Acetabular Development and Complications
- Effects of multiple low-dose intranasal dexmedetomidine administration on postoperative pulmonary complications in elderly patients undergoing thoracoscopic radical resection of lung cancer: a single-center randomized controlled trial
BibTeX
@article{dugan2026reduction,
title = {{Reduction of hemorrhagic complications after non-focal renal biopsy with pre-procedure desmopressin administration}},
author = {Bradford Dugan and Christine A. Welch and Asif Rahman and Michael V. Korona and Amy Deipolyi},
journal = {Diagnostic and Interventional Radiology},
year = {2026},
month = nov,
doi = {10.4274/dir.2026.263734},
url = {https://doi.org/10.4274/dir.2026.263734},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Reduction of hemorrhagic complications after non-focal renal biopsy with pre-procedure desmopressin administration
AU - Bradford Dugan
AU - Christine A. Welch
AU - Asif Rahman
AU - Michael V. Korona
AU - Amy Deipolyi
PY - 2026
DA - 2026/11/02
JO - Diagnostic and Interventional Radiology
DO - 10.4274/dir.2026.263734
UR - https://doi.org/10.4274/dir.2026.263734
AB - PURPOSE: Ultrasound-guided non-focal renal biopsy (NFRB), which is performed to assess systemic renal processes, is associated with a 1.5%–14% bleeding risk. The goal of this study is to evaluate the safety and efficacy of 1-deamino-8-D-arginine vasopressin (DDAVP, or desmopressin) in mitigating bleeding risk when administered prior to NFRB. METHODS: This retrospective observational study includes 158 patients who underwent NFRB between March 2022 and June 2025 at the study hospital before and after the implementation of a DDAVP administration protocol. Beginning in July 2023, every patient at the study site received intravenous DDAVP immediately before biopsy, regardless of renal function. Ultimately, 79 patients received DDAVP (the DDAVP group), and 79 did not receive the intervention (the non-DDAVP group). This study’s primary endpoint was clinically significant bleeding (resulting in unplanned admission; intervention for bleeding, such as angiography or surgery; and/or death) within 1 week of biopsy. Secondary endpoints were hyponatremia or a thromboembolic event within 1 week of biopsy. The data from patients in the two groups were compared using Mann–Whitney U tests for non-parametric data, Student’s t-tests for parametric data, and chi-squared tests for categorical data (with an alpha level of P < 0.05). RESULTS: Six of the 79 patients (8%) in the non-DDAVP group experienced a clinically significant hemorrhage, compared with 0 in the DDAVP group (P = 0.03). Sodium levels were not significantly different between the two groups post-procedure (P = 0.43). There was no significant difference in the rate of thromboembolic events between the two groups [2/79 (2.5%) in the non-DDAVP group vs. 3/79 (3.8%) in the DDAVP group; P = 1.00]. The 5 patients (out of 158; 3.2%) who experienced a thromboembolic event within 1 week of NFRB had been on anticoagulants or antiplatelet agents that were held for biopsy. CONCLUSION: DDAVP is associated with a reduction in unplanned hospitalizations and bleeding interventions (angiography and embolization) after NFRB, without an observed increase in thromboembolic events. CLINICAL SIGNIFICANCE: Routine DDAVP administration before NRFB significantly reduces clinically significant bleeding, supporting its potential role as a simple prophylactic strategy.
SN - 1305-3825
SN - 1305-3612
ER -